Hypertension  >>  Azilva (azilsartan)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Azilva (azilsartan) / Takeda
NCT02451150: A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension

Completed
3
6
Japan
Azilsartan, TAK-536
Takeda
Pediatric Hypertension
09/15
09/15
NCT02407210: Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

Unknown status
3
304
RoW
azilsartan, Olmesartan medoxomil
Jiangsu HengRui Medicine Co., Ltd.
Essential Hypertension
10/15
 
NCT02609490: Azilsartan in Chinese Patients With Mild and Moderate Hypertension

Completed
3
304
RoW
Azilsartan tablets, Azilsartan placebo tablets, Olmesartan medoxomil tablets, olmesartan medoxomil placebo tablets
Lee's Pharmaceutical Limited
Hypertension
02/17
08/18
NCT02791438: A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension

Completed
3
27
Japan
Azilsartan, TAK-536, AZILVA ®, Placebo
Takeda
Pediatric Hypertension
06/19
06/19
NCT04668157: A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure

Completed
3
9
Japan
TAK-536
Takeda
Hypertension
12/23
12/23

Download Options